Drugs / Lipofundin MCT
Lipofundin MCT
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT00798447 Comparator | Nov 2008 → Oct 2010 | digestive system cancer | B. Braun Melsungen AG | Completed | No outcome recorded |
| Phase 4 | NCT03282955 Comparator | Jan 2018 → Jul 2022 | — | B. Braun Melsungen AG | Completed | Met primary |
| Phase 4 | NCT00530738 Comparator | Sep 2007 → Jan 2014 | nutritional deficiency disease | B. Braun Melsungen AG | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipofundin MCT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00530738 ↗ |
| Known as | Lipofundin MCT/LCT | “the n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide®...” PMID 31888740 ↗ Dec 2019 |
| Known as | Medialipide | “the n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide®...” PMID 31888740 ↗ Dec 2019 |
| Modality | Other / unclassified | “i.V. fat emulsion for parenteral nutrition” NCT00530738 ↗ |
| Route | Intravenous | “i.V. fat emulsion for parenteral nutrition” NCT00530738 ↗ |